Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

There is considerable evidence to suggest that the identification and treatment of dyslipidaemia will reduce the risk of premature CHD, i.e. before the age of 65. Diagnosis of the cause of raised plasma lipid levels will enable appropriate decisions to be taken with regard to management. The cornerstone of treatment is nutritional counselling and attention to other major risk factors for CHD, p...

Secondary hyperlipidaemia.

The secondary hyperlipidaemias occur remarkably frequently, and the underlying cause of high serum lipid levels will often be missed if it is not actively sought. Diagnosis is important because the lipid abnormality responds to treatment of the primary disorder in most cases; notable exceptions to this, however, are the hyperlipidaemias associated with gout and chronic renal failure. The condit...

Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.

BACKGROUND Postprandial hyperlipidaemia is known to be a high-risk factor for atherosclerotic disease because of rapid and lasting accumulations of triglyceride-rich lipoproteins and remnants. The Niemann-Pick C1-Like 1 (NPC1L1) protein acts as an intestinal cholesterol transporter and ezetimibe, which inhibits NPC1L1, has been used in patients with hypercholesterolaemia. We investigated effect...

Management of the elderly patient with hyperlipidaemia: recent concerns.

P eople over 65 make up an ever-growing section of the community. It is estimated that these individuals account for 20% of the population in Europe and 14% in the United States of America. It has been predicted that by 2050 those aged over 80 years will represent about 25% of the elderly and 5% of the total population of the USA. In Greece, 11.5% of the general population is aged over 70 years...

Ocular contusion and hyperlipidaemia.